You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康灃生物-B(06922.HK)2024年收入5353.1萬元 同比增長30.7%
格隆匯 03-31 21:10

格隆匯3月31日丨康灃生物-B(06922.HK)公吿,截至2024年12月31日止年度的年度業績,公司實現收入5353.1萬元,同比增長30.7%;年內虧損1.11億元,同比擴大5.2%;母公司普通權益持有人應占每股虧損人民幣(0.44)元。

於報吿期間及直至本公吿日期,在產品管線及業務營運方面取得多項進展,包括但不限於:公司的心臟冷凍消融系統於2024年1月通過生產質量管理規範審查。繼於2023年12月就配套冷凍治療設備取得國家藥監局的批准及於2024年1月就一次性使用冷凍探頭取得國家藥監局的批准後,公司於2024年1月就冷凍粘連治療系統獲得上市批准。

公司的良性狹窄冷凍消融系統於2024年1月進入確證性臨牀試驗階段。公司於2024年5月就公司的抗胃食管反流系統提交註冊申請。公司於2024年7月就中國大陸呼吸介入產品與波科國際醫療貿易(上海)有限公司訂立經銷協議。

公司與廣州國家實驗室及廣州醫科大學附屬第一醫院訂立科研合作協議。公司將共同參與並完成基於液氮超低温冷凍系統研發及在肺癌消融的球囊冷凍研究。公司的惡性狹窄冷凍消融系統,集團呼吸介入產品之一,於2025年3月取得國家藥監局的批准。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account